Screening and confirmation of recombinant human erythropoietin and darbepoietin-α in spiked plasma samples from drug-free horses

Shveta Gupta, Abby Sage, Ashok K Singh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Methods for screening and confirmation of erythropoiesis stimulating glycopeptides (ESGs) such as endogenous equine erythropoietin (eEPO), recombinant human erythropoietin (rhEPO) and darbepoietin-α (DAR) have been described. Four rhEPO immunoassay kits (R&D ELISA, Diagnostic Systems Limited (DSL) ELISA, chemiluminescent IMMULITE (CHEM), and DiaSorin RIA kits) were evaluated for eEPO, rhEPO and DAR screening in basal and spiked horse samples. The R&D-ELISA detected rhEPO and DAR, but did not detect eEPO. DSL-ELISA, CHEM and DS-RIA kits detected all three ESGs. The immunoassay kits did not differentiate rhEPO and DAR. Deglycosylation of the ESGs increased the detection limits of the immunoassays. DAR, rhEPO and eEPO were extracted from positive or spiked samples by using the Affi-gel and/or immunoaffinity columns. The R&D antibodies did not retain eEPO but retained rhEPO and DAR. The antibodies from DS and DSL effectively retained all three ESGs. The isolated ESGs were confirmed by using either gel electrophoresis or MALDI-TOF-MS methods. DAR and rhEPO extracted from horse plasma were hydrolyzed using trypsin and the fragments were analyzed by the MALDI-TOF-MS for their amino acid sequence. DAR and rhEPO could be differentiated according to their intact mass-ions (m/z 29,000 for rhEPO and m/z 36,000 for DAR) or trypsin-hydrolysis products (m/z 2689 and 2359 for rhEPO and m/z 2696 and 2293 for DAR).

Original languageEnglish (US)
Pages (from-to)96-109
Number of pages14
JournalAnalytica Chimica Acta
Volume552
Issue number1-2
DOIs
StatePublished - Nov 3 2005

Fingerprint

horse
Erythropoietin
Horses
Screening
drug
immunoassay
Plasmas
plasma
Pharmaceutical Preparations
Glycopeptides
antibody
Erythropoiesis
gel
Enzyme-Linked Immunosorbent Assay
Immunoassay
hydrolysis
electrokinesis
amino acid
equine
screening

Keywords

  • Darbepoietin
  • Erythropoietin
  • MALDI-TOF

Cite this

Screening and confirmation of recombinant human erythropoietin and darbepoietin-α in spiked plasma samples from drug-free horses. / Gupta, Shveta; Sage, Abby; Singh, Ashok K.

In: Analytica Chimica Acta, Vol. 552, No. 1-2, 03.11.2005, p. 96-109.

Research output: Contribution to journalArticle

@article{f2dad420f70e4206adbf20e48cf035e7,
title = "Screening and confirmation of recombinant human erythropoietin and darbepoietin-α in spiked plasma samples from drug-free horses",
abstract = "Methods for screening and confirmation of erythropoiesis stimulating glycopeptides (ESGs) such as endogenous equine erythropoietin (eEPO), recombinant human erythropoietin (rhEPO) and darbepoietin-α (DAR) have been described. Four rhEPO immunoassay kits (R&D ELISA, Diagnostic Systems Limited (DSL) ELISA, chemiluminescent IMMULITE (CHEM), and DiaSorin RIA kits) were evaluated for eEPO, rhEPO and DAR screening in basal and spiked horse samples. The R&D-ELISA detected rhEPO and DAR, but did not detect eEPO. DSL-ELISA, CHEM and DS-RIA kits detected all three ESGs. The immunoassay kits did not differentiate rhEPO and DAR. Deglycosylation of the ESGs increased the detection limits of the immunoassays. DAR, rhEPO and eEPO were extracted from positive or spiked samples by using the Affi-gel and/or immunoaffinity columns. The R&D antibodies did not retain eEPO but retained rhEPO and DAR. The antibodies from DS and DSL effectively retained all three ESGs. The isolated ESGs were confirmed by using either gel electrophoresis or MALDI-TOF-MS methods. DAR and rhEPO extracted from horse plasma were hydrolyzed using trypsin and the fragments were analyzed by the MALDI-TOF-MS for their amino acid sequence. DAR and rhEPO could be differentiated according to their intact mass-ions (m/z 29,000 for rhEPO and m/z 36,000 for DAR) or trypsin-hydrolysis products (m/z 2689 and 2359 for rhEPO and m/z 2696 and 2293 for DAR).",
keywords = "Darbepoietin, Erythropoietin, MALDI-TOF",
author = "Shveta Gupta and Abby Sage and Singh, {Ashok K}",
year = "2005",
month = "11",
day = "3",
doi = "10.1016/j.aca.2005.07.065",
language = "English (US)",
volume = "552",
pages = "96--109",
journal = "Analytica Chimica Acta",
issn = "0003-2670",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Screening and confirmation of recombinant human erythropoietin and darbepoietin-α in spiked plasma samples from drug-free horses

AU - Gupta, Shveta

AU - Sage, Abby

AU - Singh, Ashok K

PY - 2005/11/3

Y1 - 2005/11/3

N2 - Methods for screening and confirmation of erythropoiesis stimulating glycopeptides (ESGs) such as endogenous equine erythropoietin (eEPO), recombinant human erythropoietin (rhEPO) and darbepoietin-α (DAR) have been described. Four rhEPO immunoassay kits (R&D ELISA, Diagnostic Systems Limited (DSL) ELISA, chemiluminescent IMMULITE (CHEM), and DiaSorin RIA kits) were evaluated for eEPO, rhEPO and DAR screening in basal and spiked horse samples. The R&D-ELISA detected rhEPO and DAR, but did not detect eEPO. DSL-ELISA, CHEM and DS-RIA kits detected all three ESGs. The immunoassay kits did not differentiate rhEPO and DAR. Deglycosylation of the ESGs increased the detection limits of the immunoassays. DAR, rhEPO and eEPO were extracted from positive or spiked samples by using the Affi-gel and/or immunoaffinity columns. The R&D antibodies did not retain eEPO but retained rhEPO and DAR. The antibodies from DS and DSL effectively retained all three ESGs. The isolated ESGs were confirmed by using either gel electrophoresis or MALDI-TOF-MS methods. DAR and rhEPO extracted from horse plasma were hydrolyzed using trypsin and the fragments were analyzed by the MALDI-TOF-MS for their amino acid sequence. DAR and rhEPO could be differentiated according to their intact mass-ions (m/z 29,000 for rhEPO and m/z 36,000 for DAR) or trypsin-hydrolysis products (m/z 2689 and 2359 for rhEPO and m/z 2696 and 2293 for DAR).

AB - Methods for screening and confirmation of erythropoiesis stimulating glycopeptides (ESGs) such as endogenous equine erythropoietin (eEPO), recombinant human erythropoietin (rhEPO) and darbepoietin-α (DAR) have been described. Four rhEPO immunoassay kits (R&D ELISA, Diagnostic Systems Limited (DSL) ELISA, chemiluminescent IMMULITE (CHEM), and DiaSorin RIA kits) were evaluated for eEPO, rhEPO and DAR screening in basal and spiked horse samples. The R&D-ELISA detected rhEPO and DAR, but did not detect eEPO. DSL-ELISA, CHEM and DS-RIA kits detected all three ESGs. The immunoassay kits did not differentiate rhEPO and DAR. Deglycosylation of the ESGs increased the detection limits of the immunoassays. DAR, rhEPO and eEPO were extracted from positive or spiked samples by using the Affi-gel and/or immunoaffinity columns. The R&D antibodies did not retain eEPO but retained rhEPO and DAR. The antibodies from DS and DSL effectively retained all three ESGs. The isolated ESGs were confirmed by using either gel electrophoresis or MALDI-TOF-MS methods. DAR and rhEPO extracted from horse plasma were hydrolyzed using trypsin and the fragments were analyzed by the MALDI-TOF-MS for their amino acid sequence. DAR and rhEPO could be differentiated according to their intact mass-ions (m/z 29,000 for rhEPO and m/z 36,000 for DAR) or trypsin-hydrolysis products (m/z 2689 and 2359 for rhEPO and m/z 2696 and 2293 for DAR).

KW - Darbepoietin

KW - Erythropoietin

KW - MALDI-TOF

UR - http://www.scopus.com/inward/record.url?scp=26844489615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844489615&partnerID=8YFLogxK

U2 - 10.1016/j.aca.2005.07.065

DO - 10.1016/j.aca.2005.07.065

M3 - Article

VL - 552

SP - 96

EP - 109

JO - Analytica Chimica Acta

JF - Analytica Chimica Acta

SN - 0003-2670

IS - 1-2

ER -